Plexium
San Diego, United States · Biotechnology, Health Care · 57 employees
Plexium is the premier, next-generation targeted protein degradation company, seeking to discover a wide range of monovalent target protein degraders that address the limitations of PROTACs and cereblon. The company’s platform is a proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated
Funding history
- Funding Round — $60.1M — Aug 2025
- Funding Round — $102.0M — Feb 2022
Recent signals
- Aug 25, 2025: Raised $60.1M
- Oct 01, 2024: Plexium, Inc. Appoints Jorge F. DiMartino, M.D., Ph.D. as Chief Medical Officer and Executive Vice President of Clinical and Translational Development
- Jan 16, 2024: Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO
- Feb 23, 2022: Raised $102.0M
See plans & pricing → Track Plexium’s funding, hiring, and signals — with verified contacts — on Fundz.